Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (CRBP)
CUSIP: 21833P301
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value
- Shares outstanding
- 17,685,185
- Total 13F shares
- 8,624,602
- Share change
- -259,945
- Total reported value
- $109,102,095
- Put/Call ratio
- 27%
- Price per share
- $12.65
- Number of holders
- 79
- Value change
- -$2,067,263
- Number of buys
- 32
- Number of sells
- 37
Quarterly Holders Quick Answers
What is CUSIP 21833P301?
CUSIP 21833P301 identifies CRBP - Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 21833P301:
Top shareholders of CRBP - Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP |
13F
|
Company |
13%
|
2,375,000
|
$16,387,500 | — | 30 Jun 2025 | |
| ORBIMED ADVISORS LLC |
13F
13D/G
|
Company · OrbiMed Capital LLC |
5.9%
from 13D/G
|
1,172,287
|
$8,088,780 | — | 30 Jun 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
6.3%
|
1,115,000
|
$7,693,500 | — | 30 Jun 2025 | |
| Rachael Louise Brake |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
1,400,000
|
$6,958,000 | — | 13 Feb 2023 | |
| Craig Stuart Millian |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
934,645
|
$4,645,186 | — | 13 Feb 2023 | |
| VANGUARD GROUP INC |
13F
13D/G
|
Company · The Vanguard Group |
4.9%
from 13D/G
|
599,495
|
$4,136,516 | — | 30 Jun 2025 | |
| Prosight Management, LP |
13F
|
Company |
3.3%
|
579,893
|
$4,001,262 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
2.9%
|
352,409
|
$2,431,622 | $0 | 30 Jun 2025 | |
| Exome Asset Management LLC |
13F
|
Company |
1.6%
|
277,317
|
$1,913,487 | — | 30 Jun 2025 | |
| COMERICA BANK |
13F
|
Company |
1.1%
|
200,001
|
$1,380,007 | — | 30 Jun 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
1.1%
|
192,000
|
$1,324,800 | — | 30 Jun 2025 | |
| Atle Fund Management AB |
13F
|
Company |
0.99%
|
175,582
|
$1,211,516 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.9%
|
159,162
|
$1,098,218 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.9%
|
158,999
|
$1,097,094 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.87%
|
153,539
|
$1,059,419 | — | 30 Jun 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.86%
|
152,271
|
$1,050,000 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.76%
|
134,091
|
$925,576 | — | 30 Jun 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.72%
|
127,520
|
$879,888 | — | 30 Jun 2025 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
0.67%
|
119,056
|
$821,486 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.52%
|
91,843
|
$633,717 | — | 30 Jun 2025 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.45%
|
80,347
|
$554,394 | — | 30 Jun 2025 | |
| HighVista Strategies LLC |
13F
|
Company |
0.43%
|
75,292
|
$519,515 | — | 30 Jun 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.41%
|
72,226
|
$498,359 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.41%
|
71,893
|
$496,062 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.39%
|
68,148
|
$470,221 | — | 30 Jun 2025 | |
| Velan Capital Investment Management LP |
13F
|
Company |
0.33%
|
59,000
|
$407,100 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.31%
|
55,092
|
$380,135 | — | 30 Jun 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.26%
|
45,501
|
$313,957 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.25%
|
43,674
|
$301,351 | — | 30 Jun 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.25%
|
43,332
|
$298,991 | — | 30 Jun 2025 | |
| Alan F. Holmer |
3/4/5
|
Director |
—
mixed-class rows
|
32,458
mixed-class rows
|
$254,268 | — | 30 May 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.18%
|
31,651
|
$218,392 | — | 30 Jun 2025 | |
| AlphaQuest LLC |
13F
|
Company |
0.18%
|
31,536
|
$217,598 | — | 30 Jun 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.16%
|
28,407
|
$196,008 | — | 30 Jun 2025 | |
| Avery W. Catlin |
3/4/5
|
Director |
—
mixed-class rows
|
7,133
mixed-class rows
|
$144,332 | — | 30 May 2024 | |
| Y-Intercept (Hong Kong) Ltd |
13F
|
Company |
0.12%
|
20,437
|
$141,015 | — | 30 Jun 2025 | |
| Rachelle Suzanne Jacques |
3/4/5
|
Director |
—
mixed-class rows
|
26,366
mixed-class rows
|
$140,135 | — | 30 May 2025 | |
| Yong Ben |
3/4/5
|
Director |
—
mixed-class rows
|
26,366
mixed-class rows
|
$140,135 | — | 30 May 2025 | |
| Baker Avenue Asset Management, LP |
13F
|
Company |
0.11%
|
20,000
|
$138,000 | — | 30 Jun 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.11%
|
19,871
|
$137,110 | — | 30 Jun 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.11%
|
18,878
|
$130,257 | — | 30 Jun 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.1%
|
17,898
|
$123,496 | — | 30 Jun 2025 | |
| John Kenneth Jenkins |
3/4/5
|
Director |
—
mixed-class rows
|
23,649
mixed-class rows
|
$120,582 | -$20,465 | 30 May 2025 | |
| Aster Capital Management (DIFC) Ltd |
13F
|
Company |
0.09%
|
16,509
|
$113,912 | — | 30 Jun 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.09%
|
16,340
|
$112,746 | — | 30 Jun 2025 | |
| Mariner, LLC |
13F
|
Company |
0.09%
|
15,551
|
$107,302 | — | 30 Jun 2025 | |
| Peter Salzmann |
3/4/5
|
Director |
—
mixed-class rows
|
5,566
mixed-class rows
|
$97,322 | — | 30 May 2024 | |
| Corton Capital Inc. |
13F
|
Company |
0.07%
|
12,516
|
$86,360 | — | 30 Jun 2025 | |
| Jain Global LLC |
13F
|
Company |
0.07%
|
12,369
|
$85,346 | — | 30 Jun 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.07%
|
11,548
|
$79,000 | — | 30 Jun 2025 |
Institutional Holders of Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (CRBP) as of Q3 2025
As of 30 Sep 2025,
Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (CRBP) was held by
79 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,624,602 shares.
The largest 10 holders included
Cormorant Asset Management, LP, ORBIMED ADVISORS LLC, Octagon Capital Advisors LP, VANGUARD GROUP INC, Prosight Management, LP, Exome Asset Management LLC, BlackRock, Inc., COMERICA BANK, ARMISTICE CAPITAL, LLC, and Aberdeen Group plc.
This page lists
79
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
78
Q3 2025 holders
79
Holder diff
1
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.